Vanda Pharmaceuticals Inc VNDA

NAS: VNDA | ISIN: US9216591084 18/12/2025

6,670 USD (-2,20%)

(-2,20%) 18/12/2025

Grafiek Vanda Pharmaceuticals Inc

Grafiek Vanda Pharmaceuticals Inc

1 dag1d -2,20%
1 week1w 7,06%
1 maand1m 29,77%
3 maanden3m 48,55%
6 maanden6m 47,89%
1 jaar1j 44,06%
5 jaar5j -51,56%

Vanda Pharmaceuticals Inc in het nieuws

Toon enkel gratis nieuws

15 december 2025 · Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis · Persbericht

11 december 2025 · Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference · Persbericht

4 december 2025 · FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness · Persbericht

28 november 2025 · Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness · Persbericht

18 november 2025 · Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting · Persbericht

5 november 2025 · Vanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare Conference · Persbericht

29 oktober 2025 · Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results · Persbericht

22 oktober 2025 · Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025 · Persbericht

8 oktober 2025 · Monumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena · Persbericht

1 oktober 2025 · Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration · Persbericht

Profiel Vanda Pharmaceuticals Inc

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: www.vandapharma.com

Hoofdzetel: Washington, Washington Dc Verenigde Staten

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe